雷帕霉素哺乳动物靶点（mTOR）抑制不能预防肺腺癌诱导的恶性胸腔积液。

Mammalian target of rapamycin (mTOR) inhibition does not prevent lung adenocarcinoma-induced malignant pleural effusion.

作者信息

Vazakidou Maria-Eleni, Magkouta Sofia, Moschos Charalambos, Kalomenidis Ioannis

机构信息

1st Department of Critical Care and Pulmonary Services, School of Medicine, Evangelismos Hospital, University of Athens, Athens, Greece.

出版信息

Respirology. 2014 Feb;19(2):290-292. doi: 10.1111/resp.12151. Epub 2013 Dec 25.

DOI:10.1111/resp.12151

PMID:23819792

Abstract

The impact of temsirolimus was investigated in a murine model of malignant pleural effusion (MPE) created with intrapleural injection of Lewis Lung Cancer (LLC) cells. Temsirolimus (1 or 20 mg/kg) did not affect the pleural fluid volume or the number of pleural tumour foci. In addition, temsirolimus did not affect vascular endothelial growth factor expression by LLC cells in vitro. In conclusion, temsirolimus did not curtail experimental lung-adenocarcinoma-induced MPE.

摘要

通过向小鼠胸膜腔内注射刘易斯肺癌（LLC）细胞建立恶性胸腔积液（MPE）小鼠模型，研究了替西罗莫司的影响。替西罗莫司（1或20mg/kg）不影响胸腔积液量或胸膜肿瘤灶数量。此外，替西罗莫司在体外不影响LLC细胞的血管内皮生长因子表达。总之，替西罗莫司不能减少实验性肺腺癌诱导的MPE。